Affimed Gmbh

Joachim Koch

Uwe Reusch

Erich Rajkovic

Martin Treder

Thorsten Ross

Ivica Fucek

Kristina Ellwanger

Michael Tesar

Adelheid Cerwenka

Jens Pahl

Holger J Dulat

The invention relates to an anti-CD16A antigen binding protein for use in NK cell-based immunotherapy, wherein the anti-CD16A antigen binding protein is to be administered intermittently and in combination with a cytokine. In certain embodiments the antigen binding protein is a tetravalent and bispecific CD30/CD16A tandem diabody.

Combination of an anti-CD16A antibody with a cytokine

The invention relates to multispecific antigen-binding proteins for engaging natural killer (NK) cells for triggering NK cell cytotoxicity by engaging the CD16A (Fc&#x3b3;RIIIA) expressed on NK cells, wherein the antigen-binding protein comprises at least two CD16A antigen-binding moieties and at least a further target antigen-binding moiety. The CD16A antigen-binding moiety comprises light chain and heavy chain variable regions linked one after another in a polypeptide chain and the variable region at the N-terminus of the polypeptide chain comprising the CD16A antigen-binding moiety is a light chain variable region.

NK cell engaging antibody fusion constructs

Growing community of inventors

Heidelberg, Germany

Joachim Koch